[(benzoyloxy)methyl]zinc iodide | 14135-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(benzoyloxy)methyl]zinc iodide
• 英文别名: (benzoyloxymethyl)zinc iodide；benzoyloxymethylzinc iodide；iodo{[(phenylcarbonyl)oxy]methyl}zinc；(benzoyloxymethyl)zinc(II) iodide；Benzoyloxymethylzinkiodid
• CAS: 14135-39-8
• 化学式: C₈H₇IO₂Zn
• 分子量: 327.437
• InChiKey: KGAZPROBBQPOSD-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.23
• 重原子数：
  12.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  [(benzoyloxy)methyl]zinc iodide 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 20.0h， 生成 2-[(benzoyloxy)methyl]-6-phenyl-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosyl)purine
  参考文献：
  名称：

  Synthesis of 6-Amino-, 6-Methyl- and 6-Aryl-2-(hydroxymethyl)purine Bases and Nucleosides

  摘要：

  开发了一种合成6-取代2-(羟甲基)嘌呤衍生物（碱基和核苷）的有效方法。利用区域选择性Pd催化的交叉偶联反应将6-氯-2-碘嘌呤与[(苯甲酰氧)甲基]锌碘反应，得到2-[(苯甲酰氧)甲基]-6-氯嘌呤，通过与氨反应转化为2-(羟甲基)腺嘌呤，通过与三甲基铝或芳基硼酸的交叉偶联反应后去保护，得到6-甲基或6-芳基-2-(羟甲基)嘌呤。这些6-取代2-(羟甲基)嘌呤碱基和核苷没有表现出显著的细胞毒素或抗HCV活性。

  DOI：

  10.1135/cccc20060788
• 作为产物：
  描述：

  苯甲酸氯甲基 在 1,2-二溴乙烷 、 sodium iodide 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 2.0h， 生成 [(benzoyloxy)methyl]zinc iodide
  参考文献：
  名称：

  [EN] INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR
  [FR] MODULATEURS INDOLES ET AZAINDOLES DU NACHR-?7

  摘要：

  这项发明涉及利用式(I)的化合物或其药用可接受盐对α7尼古丁乙酰胆碱受体(nAChR)进行调节。

  公开号：

  WO2011045353A1

文献信息

• [EN] PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANALOGUES DE PYRIDONE UTILES COMME ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE CONCENTRANT LA MÉLANINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010104830A1

  公开（公告）日：2010-09-16

  MCHR1 antagonists are provided having the following Formula I: wherein A1 and A2 are independently C or N; E is C or N; D1 is a bond, -CR8R9X-, -XCR8R9-, -CHR8CHR9-, -CR10=CR10'-, -C≡C-, or 1,2-cyclopropyl; X is O, S or -NR11; R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, lower cycloalkoxy, -CF3, -OCF3, -OR12 and -SR12; G is O or S; D2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkycycloalkoxy; Z1 and Z2 are independently hydrogen, halogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF3, -OCONR14R14', -CN, -CONR14R14', -SOR12, -SO2R12, -NR14COR14', -NR14CO2R14', -CO2R12, NR14SO2R12 or -COR12 provided that if Z1 is -CH3 and one of R1, R2, or R3 is F, then Z2 cannot be H;; R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF3, -SR12, lower alkoxy, lower cycloalkoxy, -OCH2OMe, -CN, -CONR14R14', SOR12, SO2R12, NR14COR14', NR14CO2R12, CO2R12, NR14SO2R12 and -COR12; R8, R9, R10, R10', R11 are independently hydrogen or lower alkyl; R12 is lower alkyl or lower cycloalkyl; and R14 and R14' are independently H, lower alkyl, lower cycloalkyl or R14 and R14' together with the N to which they are attached form a ring having 4 to 7 atoms. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

  MCHR1拮抗剂具有以下的化学式I：其中A1和A2独立地为C或N；E为C或N；D1为键，-CR8R9X-，-XCR8R9-，-CHR8CHR9-，-CR10=CR10'-，-C≡C-，或1,2-环丙基；X为O，S或-NR11；R1、R2和R3独立地选自氢、卤素、低烷基、低环烷基、低环氧基、-CF3、-O 、-OR12和-SR12的组；G为O或S；D2为低烷基、低环烷基、低烷基环烷基、低环烷基烷基、低环氧基烷基或低烷基环氧基；Z1和Z2独立地为氢、卤素、低烷基、低环烷基、低烷氧基、低环氧基、卤、- 、-OCONR14R14'、-CN、-CONR14R14'、-SOR12、-SO2R12、-NR14COR14'、-NR14CO2R14'、-CO2R12、NR14SO2R12或-COR12，但如果Z1为-CH3且R1、R2或R3中有一个为F，则Z2不能为H；R5、R6和R7独立地选自氢、卤素、低烷基、低环烷基、- 、-SR12、低烷氧基、低环氧基、-OCH2OMe、-CN、-CONR14R14'、SOR12、SO2R12、NR14COR14'、NR14CO2R12、CO2R12、NR14SO2R12和-COR12；R8、R9、R10、R10'、R11独立地为氢或低烷基；R12为低烷基或低环烷基；R14和R14'独立地为H、低烷基、低环烷基或R14和R14'与它们连接的N一起形成具有4至7个原子的环。这类化合物对于治疗MCHR1介导的疾病，如肥胖症、糖尿病、炎症性肠病、抑郁症和焦虑症是有用的。
• [EN] NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES<br/>[FR] NOUVEAUX NUCLÉOSIDES 7-DÉAZAPURINE CYTOSTATIQUES
  申请人：ACAD OF SCIENCE CZECH REPUBLIC

  公开号：WO2009089804A1

  公开（公告）日：2009-07-23

  The invention provides compounds of formula (I), wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.

  这项发明提供了式（I）的化合物，其中R1和R2具有规范中定义的任何值及其盐，以及包含这些化合物的组合物和利用这些化合物的治疗方法。
• Hydroxymethylations of Aryl Halides by Pd-Catalyzed Cross-Couplings with (Benzoyloxy)methylzinc Iodide - Scope and Limitations of the Reaction
  作者：Michal Hocek、Zbyněk Hasník、Peter Šilhár

  DOI：10.1055/s-2008-1032084

  日期：——

  Palladium-catalyzed cross-coupling reactions of (benzoyloxymethyl)zinc iodide with diverse (het)aryl halides leading to (benzoyloxymethyl)(het)arenes were studied to define the scope of this reaction. It has been found that this reaction is only applicable for electron-deficient aryl halides and the most efficient it is for 2-halopyridines and 4-halopyrimidines. Deprotection of the intermediates gives

  研究了钯催化的（苯甲酰氧基甲基）碘化锌与多种（杂）芳基卤化物产生（苯甲酰氧基甲基）（杂）芳烃的交叉偶联反应，以确定该反应的范围。已发现该反应仅适用于缺电子的芳基卤化物，并且最有效的是用于 2-卤代吡啶和 4-卤代嘧啶。中间体的脱保护以高产率得到(羟甲基)吡啶和-嘧啶。
• Cytostatic and Antiviral 6-Arylpurine Ribonucleosides VIII. Synthesis and Evaluation of 6-Substituted Purine 3'-Deoxyribonucleosides
  作者：Michal Hocek、Peter Šilhár、Radek Pohl

  DOI：10.1135/cccc20061484

  日期：——

  A series of purine 3'-deoxyribonucleosides bearing diverse C-substituents (alkyl, aryl, hetaryl or hydroxymethyl) in the position 6 was prepared by Pd-catalyzed cross-coupling reactions of 6-iodo-9-[2,5-bis-O-(tert-butyldimethylsilyl)-3-deoxy-β-D-ribofuranosyl]purine with the corresponding organometallics followed by deprotection by (HF)₃·Et₃N. None of the title 3'-deoxyribonucleoside showed any cytostatic activity or anti-HCV effect in replicon assay.

  一系列带有不同C-取代基（烷基，芳基，杂环基或羟甲基）的嘌呤3'-去氧核糖核苷在Pd催化的交叉偶联反应中制备，该反应通过6-碘-9-[2,5-双-O-(叔-丁基二甲基硅基)-3-去氧-β-D-核糖呋喃核苷基]嘌呤与相应的有机金属化合物进行反应，然后通过（HF）₃·Et₃N去保护基团。在复制体试验中，这些标题的3'-去氧核糖核苷均未显示出任何细胞静止活性或抗HCV效果。
• Cytostatic and antiviral 6-arylpurine ribonucleosides. Part 7: Synthesis and evaluation of 6-substituted purine l-ribonucleosides
  作者：Michal Hocek、Peter Šilhár、I-hung Shih、Eric Mabery、Richard Mackman

  DOI：10.1016/j.bmcl.2006.07.092

  日期：2006.10

  A series of purine l-ribonucleosides 2a-2i bearing diverse C-substituents (alkyl, aryl, hetaryl or hydroxymethyl) in the position 6 were prepared by Pd-catalyzed cross-coupling reactions of 6-chloro-9-(2,3,5-tri-O-acetyl-beta-l-ribofuranosyl)purine with the corresponding organometallics followed by deprotection. Unlike their d-ribonucleoside enantiomers that possess strong cytostatic and anti-HCV activity

  通过Pd催化6-氯-9-（2,3， 5-三-O-乙酰基-β-1-核呋喃糖基）嘌呤与相应的有机金属，然后脱保护。不同于具有强大的细胞生长抑制作用和抗HCV活性的d-核糖核苷对映异构体，l-核糖核苷是无活性的，除了6-苄嘌呤核苷2h在复制子测定中显示出中等的抗HCV作用。2h的三磷酸酯不抑制HCV RNA聚合酶。